Price (delayed)
$12.98
Market cap
$433.57M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.93
Enterprise value
$402.2M
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our investigational product, HEPZATO KIT™ (melphalan hydrochloride for injection/hepatic delivery system), is
There are no recent dividends present for DCTH.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from and Sharadar.